Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | AVPR2 | P30518 | 8/20 | 0.64 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.63 |
| ▸ | OXTR | P30559 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120560 | 0.95 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMALDH1A1POLBKDM4E | |
| SCHEMBL29640094 | 0.95 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMALDH1A1POLBKDM4E | |
| SCHEMBL29443491 | 0.87 | NOTUM (0.68) | SMN1; SMN2NOTUMALDH1A1POLBPKM | |
| SCHEMBL43169 | 0.87 | NOTUM (0.68) | SMN1; SMN2NOTUMALDH1A1POLBPKM | |
| SCHEMBL30829142 | 0.86 | NOTUM (0.63) | SMN1; SMN2NOTUMALDH1A1POLBKDM4E | |
| SCHEMBL30829143 | 0.86 | NOTUM (0.63) | SMN1; SMN2NOTUMALDH1A1POLBKDM4E | |
| Hydrochloric Acid SCHEMBL29858239 | 0.86 | NOTUM (0.66) | SMN1; SMN2NOTUMALDH1A1POLBPKM | |
| Hydrochloric Acid SCHEMBL5573069 | 0.86 | NOTUM (0.66) | SMN1; SMN2NOTUMALDH1A1POLBPKM | |
| SCHEMBL30456228 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2AVPR2AVPR1ANOTUMOXTR | |
| SCHEMBL5423105 | 0.83 | NOTUM (0.90) | SMN1; SMN2AVPR2AVPR1ANOTUMOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | SMN1; SMN2 1323/4885AVPR2 600/4885AVPR1A 611/4885 |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | SMN1; SMN2 2595/4885AVPR2 124/4885AVPR1A 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.